01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Becton Dickinson and Company (BDX) reported solid revenue growth in the third quarter of fiscal year 2024, with total revenues reaching $4.99 billiona, a 2.3% increase year-over-year.
This growth was driven by strong performance in the Medical and Interventional segments, particularly in Medication Delivery Solutions and Urology and Critical Care, respectively. Net income for the quarter was $487 millionb, resulting in diluted earnings per share of $1.68, an improvement from $1.36 in the prior year's quarter. The company continues to strengthen its financial position, demonstrated by a significant increase in cash and equivalents and the successful issuance of new debt to fund strategic initiatives.
A significant development during the quarter was the announcement of the definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billionc. This strategic acquisition is expected to enhance BD's smart connected care solutions and is anticipated to close by the end of calendar year 2024, subject to regulatory approvals.
The company also provided updates on ongoing legal matters, including product liability claims and regulatory investigations, noting a $50 milliond charge related to an SEC investigation into Alaris infusion pumps. Overall, BDX demonstrated resilience and strategic foresight, balancing operational execution with significant growth opportunities.
02—Key points
Key Highlights
- Total revenues increased by 2.3% to $4.99 billion in Q3 FY24, driven by strong performance in the Medical and Interventional segments.
- Net income rose to $487 million, with diluted EPS improving to $1.68 from $1.36 in the prior-year period.
- Announced a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion, expected to close by year-end 2024.
- Operating cash flow for the nine months ended June 30, 2024, was robust at $2.67 billion.
- The company issued new debt in June 2024 to fund the upcoming acquisition and for general corporate purposes.
- Product liability accruals decreased to $1.7 billion as of June 30, 2024, compared to $1.9 billion at September 30, 2023, largely due to settlements and favorable claim resolutions.
- Cash and equivalents and short-term investments increased significantly to $5.338 billion as of June 30, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Becton Dickinson & Co kept $0.10.
- Revenue$4.99B100.0%
- Cost of revenue−$2.68B53.8%
- Gross profit$2.31B46.2%
- Operating costs−$1.71B34.2%
- Operating income$602.0M12.1%
- Interest, other & tax−$115.0M2.3%
- Net income$487.0M9.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed August 1, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $4.99B$4.88B | +2.3% |
| Cost of Revenue | $2.68B$2.78B | −3.4% |
| Gross Profit | $2.31B$2.10B | +9.9% |
| R&D Expenses | $299.00M$306.00M | −2.3% |
| SG&A Expenses | $1.20B$1.19B | +0.5% |
| Operating Expenses | $4.39B$4.33B | +1.4% |
| Operating Income | $602.00M$549.00M | +9.7% |
| Net Income | $487.00M$407.00M | +19.7% |
| EPS (Basic) | $1.68$1.37 | +22.6% |
| EPS (Diluted) | $1.68$1.36 | +23.5% |
| Shares Outstanding (Basic) | 289.56M286.32M | +1.1% |
| Shares Outstanding (Diluted) | 290.25M287.94M | +0.8% |
05—Questions
Frequently Asked Questions
What was BDX's revenue and profit performance in the third quarter of fiscal year 2024?
In the third quarter of fiscal year 2024, BDX reported total revenues of $4.99 billion, a 2.3% increase compared to the prior year. Net income was $487 million, and diluted earnings per share (EPS) were $1.68, up from $1.36 in the same quarter last year.
What are the key strategic initiatives BDX is undertaking?
BDX announced a significant strategic move to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition aims to expand BD's portfolio of smart connected care solutions. Additionally, the company is executing its 'BD 2025' strategy focused on growth, simplification, and empowerment, which includes investments in R&D, acquisitions, and operational efficiency.
How is BDX managing its financial resources and debt?
BDX generated strong operating cash flow of $2.67 billion for the first nine months of fiscal year 2024. The company issued new debt in June 2024 to help fund the Critical Care acquisition and for general corporate purposes, increasing its total debt to $19.32 billion as of June 30, 2024. Cash and equivalents, along with short-term investments, increased substantially to $5.34 billion, providing ample liquidity.
What are the significant legal and regulatory matters affecting BDX?
BDX is involved in various legal proceedings, including approximately 38,800 product liability claims related to hernia repair devices and other mass tort litigations. The company also recorded a $50 million charge related to an ongoing SEC investigation concerning Alaris infusion pumps. While significant, the company believes it has meritorious defenses in most matters, and the product liability accrual has decreased.
06—Continue